Melissa Trombetta - Viatris Head Relations
| VTRS Stock | USD 13.09 0.13 0.98% |
Insider
Melissa Trombetta is Head Relations of Viatris
| Address | 1000 Mylan Boulevard, Canonsburg, PA, United States, 15317 |
| Phone | 724 514 1800 |
| Web | https://www.viatris.com |
Viatris Management Efficiency
The company has return on total asset (ROA) of 0.0248 % which means that it generated a profit of $0.0248 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0434) %, meaning that it created substantial loss on money invested by shareholders. Viatris' management efficiency ratios could be used to measure how well Viatris manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to 0 in 2024. Return On Capital Employed is likely to drop to 0.02 in 2024. At this time, Viatris' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 36.4 B in 2024, whereas Net Tangible Assets are likely to drop (11.3 B) in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Karen Smith | Emergent Biosolutions | 52 | |
| ACGI BSc | HUTCHMED DRC | 70 | |
| MBA MBA | Dr Reddys Laboratories | 55 | |
| Robert Kelly | Zoetis Inc | 48 | |
| Salvatore Alesci | Takeda Pharmaceutical Co | N/A | |
| CS CGP | HUTCHMED DRC | 70 | |
| Abhay Nayak | Zoetis Inc | 32 | |
| William Price | Zoetis Inc | N/A | |
| Steven Esq | Catalent | 61 | |
| Shawn McKee | Elanco Animal Health | N/A | |
| Robert Polzer | Zoetis Inc | 55 | |
| Norimasa Takeda | Takeda Pharmaceutical Co | N/A | |
| Seigo Izumo | Takeda Pharmaceutical Co | N/A | |
| Timothy Bettington | Zoetis Inc | 46 | |
| Abbas Hussain | Teva Pharma Industries | 55 | |
| Lynn Kieffer | Emergent Biosolutions | N/A | |
| Olivier Bohuon | Takeda Pharmaceutical Co | 61 | |
| K Singh | Dr Reddys Laboratories | N/A | |
| Erez MBA | Dr Reddys Laboratories | 56 | |
| Robert Butz | Bausch Health Companies | N/A | |
| Karen Flynn | Catalent | 56 | |
Management Performance
| Return On Equity | -0.0434 | ||||
| Return On Asset | 0.0248 |
Viatris Leadership Team
Elected by the shareholders, the Viatris' board of directors comprises two types of representatives: Viatris inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Viatris. The board's role is to monitor Viatris' management team and ensure that shareholders' interests are well served. Viatris' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Viatris' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Melissa Trombetta, Head Relations | ||
| Andrew Enrietti, Chief Officer | ||
| Anthony Mauro, President Markets | ||
| Theodora Mistras, Chief Officer | ||
| David Bayles, Chief Officer | ||
| Sanjeev Sethi, Chief Officer | ||
| Ramkumar Rayapureddy, Chief Officer | ||
| Paul Campbell, Senior Officer | ||
| Rajiv Malik, President Director | ||
| PharmD MBA, Chief Officer | ||
| Brian Roman, Global Counsel | ||
| Philippe Martin, Chief Officer | ||
| Derek Glover, Chief Officer | ||
| Scott Smith, CEO Director | ||
| Jeffrey MMS, President Division | ||
| Menassie MBA, President Markets | ||
| Robert Coury, Ex Chairman | ||
| Lara Ramsburg, Chief Officer | ||
| Sanjeev Narula, Chief Officer | ||
| Jennifer Mauer, Head Brand | ||
| Michael Goettler, CEO Director |
Viatris Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Viatris a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0434 | ||||
| Return On Asset | 0.0248 | ||||
| Profit Margin | (0.06) % | ||||
| Operating Margin | 0.14 % | ||||
| Current Valuation | 29.6 B | ||||
| Shares Outstanding | 1.19 B | ||||
| Shares Owned By Insiders | 0.41 % | ||||
| Shares Owned By Institutions | 82.80 % | ||||
| Number Of Shares Shorted | 20.71 M | ||||
| Price To Earning | 15.16 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Viatris Stock Analysis
When running Viatris' price analysis, check to measure Viatris' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viatris is operating at the current time. Most of Viatris' value examination focuses on studying past and present price action to predict the probability of Viatris' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viatris' price. Additionally, you may evaluate how the addition of Viatris to your portfolios can decrease your overall portfolio volatility.